Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem

DUBLIN, Ireland and CHICAGO, July 26, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the“Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news